CARCINOMA, RENAL CELL
Clinical trials for CARCINOMA, RENAL CELL explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, RENAL CELL trials appear
Sign up with your email to follow new studies for CARCINOMA, RENAL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World data shows promise for kidney cancer drug combo
Disease control CompletedThis completed study looked at how well avelumab (BAVENCIO) plus axitinib (INLYTA) works for advanced kidney cancer in everyday medical practice. Researchers tracked 105 patients across multiple EU countries to see survival rates at 12 and 24 months. The goal was to understand th…
Matched conditions: CARCINOMA, RENAL CELL
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New kidney cancer drug shows promise in early trial
Disease control CompletedThis early-stage trial tested a drug called belzutifan in 29 people with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to check safety and find the right dose. Participants took belzutifan pills daily, and researchers monitored side…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Matched conditions: CARCINOMA, RENAL CELL
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immunotherapy combo before kidney surgery shows promise in small trial
Disease control CompletedThis early-phase study tested two immunotherapy drugs (spartalizumab and canakinumab) given before surgery to 17 people with localized clear cell kidney cancer. The main goal was to see if this approach was safe and did not delay surgery. The study also looked at how the drugs af…
Matched conditions: CARCINOMA, RENAL CELL
Phase: EARLY_PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Matched conditions: CARCINOMA, RENAL CELL
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC